Last Updated: August 9, 2026

Details for Patent: 4,324,779

Name: Drug Patent Intelligence for US Patent 4324779
Creator: DrugPatentWatch
License: https://www.drugpatentwatch.com/terms.php

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 4,324,779

Title:	Method for treating hypertonia with N-(2-furfuryl)-4-chloro-5-sulfamoyl-anthranilic acid and preparations thereof
Abstract:	A method for treating hypertonia with a preparation of N-(2-furfuryl)-4-chloro-5-sulfamoyl-anthranilic acid having a slightly retarded release, wherein the release of the active substance in vitro, measured in the flow through-cell to Dibbern, is not more than 5% after 1 hour in a buffer solution of pH 1.5 and about 10 to at most 25% of the active substance content after a two-hour treatment in a buffer solution of pH 5.5.
Inventor(s):	Gebhard Dahlhausen, Hans-Werner Dibbern, Fulberth, Gerhard Ross
Assignee:	Sanofi Aventis Deutschland GmbH
Application Number:	US06/077,181
Patent Claim Types: see list of patent claims	Formulation; Compound; Dosage form;
Patent landscape, scope, and claims:	error: insufficient information More… ↓ ⤷ Start Trial

Drugs Protected by US Patent 4,324,779

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Foreign Priority and PCT Information for Patent: 4,324,779

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Germany	2343218	Aug 28, 1973

International Family Members for US Patent 4,324,779

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	344914	⤷ Start Trial
Austria	A694274	⤷ Start Trial
Australia	7272874	⤷ Start Trial
Belgium	819294	⤷ Start Trial
Canada	1063024	⤷ Start Trial
Germany	2343218	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.